Spain strangles brands as PPP falls to 14-year low
This article was originally published in Scrip
More angst for the producers of innovative and branded drugs as the latest figures from Spain indicate that the total drug spend down 4.45% in the first quarter of 2012 compared to the same period in 2011, despite the fact that the number of paid prescriptions issued rose by 2.19%.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.